SK Biopharm’s Xcopri Launches in Korea With Insurance Coverage[K-Bio Pulse]

SK Biopharmaceuticals’ epilepsy drug Xcopri entered the Korean market with national health insurance coverage.

According to KG Zeroin’s MP DOCTOR market data service, SK Biopharmaceuticals closed at KRW 79,200, up KRW 1,700, or 2.19%, from the previous session.

“We will work to help patients reduce the disruption seizures cause in their daily lives and maintain consistent treatment.” SK Biopharmaceuticals signed a licensing agreement with Dong-A ST in January 2024 covering 30 countries, including South Korea.